Arcus Biosciences Stock Current Valuation
| RCUS Stock | USD 15.44 0.36 2.28% |
Valuation analysis of Arcus Biosciences helps investors to measure Arcus Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 2.6 B in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (4.36). Fundamental drivers impacting Arcus Biosciences' valuation include:
Price Book 2.5008 | Enterprise Value 381.9 M | Enterprise Value Ebitda 3.9599 | Price Sales 5.4977 | Enterprise Value Revenue 1.4522 |
Undervalued
Today
Please note that Arcus Biosciences' price fluctuation is not too volatile at this time. Calculation of the real value of Arcus Biosciences is based on 3 months time horizon. Increasing Arcus Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arcus stock is determined by what a typical buyer is willing to pay for full or partial control of Arcus Biosciences. Since Arcus Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcus Stock. However, Arcus Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.44 | Real 22.31 | Target 43.08 | Hype 15.43 | Naive 16.25 |
The intrinsic value of Arcus Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcus Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcus Biosciences helps investors to forecast how Arcus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcus Biosciences more accurately as focusing exclusively on Arcus Biosciences' fundamentals will not take into account other important factors: Arcus Biosciences Company Current Valuation Analysis
Arcus Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcus Biosciences Current Valuation | 381.94 M |
Most of Arcus Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcus Biosciences is extremely important. It helps to project a fair market value of Arcus Stock properly, considering its historical fundamentals such as Current Valuation. Since Arcus Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcus Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcus Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Arcus Current Valuation Historical Pattern
Today, most investors in Arcus Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcus Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arcus Biosciences current valuation as a starting point in their analysis.
Arcus Biosciences Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcus Biosciences has a Current Valuation of 381.94 M. This is 97.34% lower than that of the Biotechnology sector and 91.78% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.7% higher than that of the company.
Arcus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in current valuation category among its peers.
Arcus Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcus Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcus Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Arcus Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.03) % | ||||
| Operating Margin | (2.19) % | ||||
| Current Valuation | 381.94 M | ||||
| Shares Outstanding | 91.51 M | ||||
| Shares Owned By Insiders | 40.00 % | ||||
| Shares Owned By Institutions | 60.05 % | ||||
| Number Of Shares Shorted | 7.57 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 5.50 X | ||||
| Revenue | 117 M | ||||
| Gross Profit | (176 M) | ||||
| EBITDA | (283 M) | ||||
| Net Income | (307 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 11 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 6.17 X | ||||
| Cash Flow From Operations | (306 M) | ||||
| Short Ratio | 8.48 X | ||||
| Earnings Per Share | (3.19) X | ||||
| Target Price | 33.2 | ||||
| Number Of Employees | 577 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 1.45 B | ||||
| Total Asset | 1.09 B | ||||
| Retained Earnings | (849 M) | ||||
| Working Capital | 647 M | ||||
| Net Asset | 1.09 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.